KR20200010275A - 5,6-융합-이환식 화합물 및 기생충 질환 치료용 조성물 - Google Patents

5,6-융합-이환식 화합물 및 기생충 질환 치료용 조성물 Download PDF

Info

Publication number
KR20200010275A
KR20200010275A KR1020197034689A KR20197034689A KR20200010275A KR 20200010275 A KR20200010275 A KR 20200010275A KR 1020197034689 A KR1020197034689 A KR 1020197034689A KR 20197034689 A KR20197034689 A KR 20197034689A KR 20200010275 A KR20200010275 A KR 20200010275A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
independently selected
ring
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197034689A
Other languages
English (en)
Korean (ko)
Inventor
얀 이리체크
이사벨 케이. 레라리오
팡 리앙
샤오둥 류
발렌티나 몰테니
애드바이트 수레시 네이글
수이 펄리 응
막심 라트니코프
제프리 엠. 스미스
융핑 셰
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20200010275A publication Critical patent/KR20200010275A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020197034689A 2017-05-31 2018-05-29 5,6-융합-이환식 화합물 및 기생충 질환 치료용 조성물 Withdrawn KR20200010275A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762513211P 2017-05-31 2017-05-31
US62/513,211 2017-05-31
US201762581919P 2017-11-06 2017-11-06
US62/581,919 2017-11-06
PCT/IB2018/053818 WO2018220531A1 (en) 2017-05-31 2018-05-29 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases

Publications (1)

Publication Number Publication Date
KR20200010275A true KR20200010275A (ko) 2020-01-30

Family

ID=62749123

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197034689A Withdrawn KR20200010275A (ko) 2017-05-31 2018-05-29 5,6-융합-이환식 화합물 및 기생충 질환 치료용 조성물

Country Status (26)

Country Link
US (2) US11384078B2 (enExample)
EP (1) EP3630771B1 (enExample)
JP (1) JP7187490B2 (enExample)
KR (1) KR20200010275A (enExample)
CN (1) CN110678468B (enExample)
AR (1) AR111826A1 (enExample)
AU (1) AU2018276190B2 (enExample)
BR (1) BR112019024804A2 (enExample)
CA (1) CA3060990A1 (enExample)
CL (1) CL2019003467A1 (enExample)
CO (1) CO2019013254A2 (enExample)
CR (1) CR20190545A (enExample)
CU (1) CU24543B1 (enExample)
DO (1) DOP2019000299A (enExample)
EC (1) ECSP19084722A (enExample)
ES (1) ES2927207T3 (enExample)
IL (1) IL270927B (enExample)
JO (1) JOP20190278A1 (enExample)
MA (1) MA50495A (enExample)
MX (1) MX389106B (enExample)
PE (1) PE20201148A1 (enExample)
PH (1) PH12019502652A1 (enExample)
RU (1) RU2738647C1 (enExample)
TW (1) TW201902894A (enExample)
UY (1) UY37745A (enExample)
WO (1) WO2018220531A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
EP4136066A1 (en) * 2020-04-17 2023-02-22 DSM IP Assets B.V. A process for preparation of substituted enamine compounds
CN113831320B (zh) * 2020-06-23 2024-04-05 上海美悦生物科技发展有限公司 一种稠和吡唑类化合物的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10053275A1 (de) * 2000-10-27 2002-05-02 Dresden Arzneimittel Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
UA81453C2 (en) 2003-02-27 2008-01-10 Pyrazolopyridine derivates
WO2012116246A2 (en) 2011-02-25 2012-08-30 Dow Agrosciences Llc Pesticidal compostions and processes related thereto
WO2013067302A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
LT2925757T (lt) 2012-11-19 2017-12-27 Novartis Ag Junginiai ir kompozicijos, skirti parazitinių ligų gydymui
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
JP6392352B2 (ja) * 2013-12-19 2018-09-19 ノバルティス アーゲー リーシュマニア症などの寄生虫病を処置するための原生動物のプロテアソーム阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体
ES2700352T3 (es) 2014-12-02 2019-02-15 Bayer Cropscience Ag Compuestos bicíclicos como pesticidas
CN107635984B (zh) 2015-03-11 2021-04-13 Fmc公司 杂环取代的二环唑杀有害生物剂
AR104749A1 (es) * 2015-05-29 2017-08-09 Glaxosmithkline Ip Dev Ltd Imidazo[1,2-b][1,2,4]triazina sustituida, composición farmacéutica y combinación que lo comprenden, y su uso para la fabricación de un medicamento
ES2856899T3 (es) * 2015-08-07 2021-09-28 Glaxosmithkline Ip Dev Ltd Compuestos
CU24516B1 (es) 2016-05-03 2021-05-12 Bayer Pharma AG Derivados aromáticos de sulfonamida útiles como medicamentos contra enfermedades asociadas con dolor
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية

Also Published As

Publication number Publication date
PE20201148A1 (es) 2020-10-26
CA3060990A1 (en) 2018-12-06
JP2020521775A (ja) 2020-07-27
WO2018220531A1 (en) 2018-12-06
TW201902894A (zh) 2019-01-16
JP7187490B2 (ja) 2022-12-12
AU2018276190B2 (en) 2020-05-14
CN110678468B (zh) 2022-07-29
MX2019014321A (es) 2020-02-05
US20200109142A1 (en) 2020-04-09
EP3630771A1 (en) 2020-04-08
RU2738647C1 (ru) 2020-12-15
MX389106B (es) 2025-03-20
AU2018276190A1 (en) 2019-11-07
DOP2019000299A (es) 2019-12-15
EP3630771B1 (en) 2022-06-29
IL270927A (en) 2020-01-30
PH12019502652A1 (en) 2020-07-13
CL2019003467A1 (es) 2020-03-13
MA50495A (fr) 2021-04-28
ES2927207T3 (es) 2022-11-03
ECSP19084722A (es) 2019-12-27
CU20190095A7 (es) 2020-10-20
BR112019024804A2 (pt) 2020-06-09
CR20190545A (es) 2020-01-15
JOP20190278A1 (ar) 2019-11-28
US20220324863A1 (en) 2022-10-13
CO2019013254A2 (es) 2020-01-17
AR111826A1 (es) 2019-08-21
CN110678468A (zh) 2020-01-10
US11384078B2 (en) 2022-07-12
IL270927B (en) 2022-01-01
UY37745A (es) 2019-01-02
CU24543B1 (es) 2021-08-06

Similar Documents

Publication Publication Date Title
TW202210470A (zh) 靶向蛋白降解化合物及其製備方法和應用
CN117355299A (zh) 取代的2-(2,6-二氧代哌啶-3-基)-5-(1-哌啶-4-基)异吲哚啉-1,3-二酮衍生物及其用途
KR102359707B1 (ko) 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
US20220324863A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
CA2920537C (en) Piperidine urea derivatives as inhibitors of tankyrase
CA3093706A1 (en) Jak inhibitors
TW202341987A (zh) 一種Polθ抑制劑
WO2019189555A1 (ja) 複素環化合物
EP4577549A1 (en) Compounds and methods for modulating her2
WO2019244049A1 (en) Cyanotriazole compounds and uses thereof
WO2021080013A1 (en) Inhibitors of trek (twik related k+ channels) channel function
EA039324B1 (ru) 5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
JP2026502170A (ja) リガンド標的ｉｒａｋ３分解剤としての置換イミダゾ系化合物
CN117843567A (zh) 双氮杂芳环取代的苯衍生物及其组合物和用途
WO2025140656A1 (en) Heteroaryl compounds as multi-target protein kinase inhibitors
KR20260053336A (ko) Erk의 활성 조절을 위한 화합물 및 조성물
HK40105522A (en) Parp1 inhibitors and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191125

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210511

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20230424

WITB Written withdrawal of application